Literature DB >> 12764607

Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils.

Katherine B Pryzwansky1, Victoria J Madden.   

Abstract

Persistent elevations of cAMP levels are generally accompanied by an inhibition of granulocyte functions. Phosphodiesterases play a critical role in regulating intracellular levels of cAMP. The expression of three isoforms of type 4 cAMP-specific phosphodiesterase (PDE4) in neutrophils suggests diversity of isoform localization and targeting in regulating cell function. The sites of cAMP regulation in granulocytes by the PDE4A isoform were investigated by immunoelectron microscopy. PDE4A was localized uniformly in all granule classes of eosinophils, but was restricted in neutrophils to a subset of myeloperoxidase (MPO)-containing granules that were round or elongated with a central crystalloid core. Granulocytes were stimulated with fMLP to investigate the sites of PDE4A targeting during cell activation. In neutrophils, fMLP induced a rapid (1 min) translocation of granules containing PDE4A to the plasmalemma, where some PDE4A and MPO were exocytosed. In these cells, PDE4A labeling within granules was focal and no longer homogeneous. While immunogold labeling of PDE4A was reduced after fMLP stimulation, staining of MPO-containing granules remained high. Extracellular release of PDE4A was also observed in eosinophils stimulated with fMLP. Morphometry revealed that Au labeling was significantly reduced within 1 min, and that there was a shift in PDE4A localization within eosinophil granules from the crystalline core to the matrix. Fluctuations of cAMP levels and ectoprotein kinase activity with PKA properties occur in blood under normal and pathological conditions. The exclusive localization of PDE4A within granules of neutrophils and eosinophils suggests that PDE4A may function to downregulate cAMP signaling at the cell membrane and/or in the extracellular space at the time of granule release.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12764607     DOI: 10.1007/s00441-003-0728-y

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  5 in total

1.  A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury.

Authors:  Feng Bao; Jennifer C Fleming; Roozbeh Golshani; Damien D Pearse; Levent Kasabov; Arthur Brown; Lynne C Weaver
Journal:  J Neurotrauma       Date:  2011-05-05       Impact factor: 5.269

Review 2.  Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Dave Singh; Simon Lea; Alexander G Mathioudakis
Journal:  Drugs       Date:  2021-11-03       Impact factor: 9.546

Review 3.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

4.  Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

Authors:  Gail M Gauvreau; Louis-Philippe Boulet; Christine Schmid-Wirlitsch; Johanne Côté; Mylinh Duong; Kieran J Killian; Joanne Milot; Francine Deschesnes; Tara Strinich; Richard M Watson; Dirk Bredenbröker; Paul M O'Byrne
Journal:  Respir Res       Date:  2011-10-26

5.  Rolipram, a Selective Phosphodiesterase 4 Inhibitor, Ameliorates Mechanical Hyperalgesia in a Rat Model of Chemotherapy-Induced Neuropathic Pain through Inhibition of Inflammatory Cytokines in the Dorsal Root Ganglion.

Authors:  Hee Kee Kim; Seon-Hee Hwang; Elizabeth Oh; Salahadin Abdi
Journal:  Front Pharmacol       Date:  2017-12-04       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.